160 related articles for article (PubMed ID: 28968891)
1. Anti-TIF1-γ autoantibodies-positive dermatomyositis: where is the malignancy?
Zachou A; Zouvelou V; Papadimas GK; Rentzos M; Papadopoulos C
Rheumatology (Oxford); 2018 Apr; 57(4):756. PubMed ID: 28968891
[No Abstract] [Full Text] [Related]
2. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
3. The clinical spectrum of dermatomyositis and the new autoantibodies - with regard to two clinical cases with distinct associations.
Calvão da Silva JCM; Santiago L; Brites MM; Gonçalo M
Australas J Dermatol; 2020 May; 61(2):e241-e243. PubMed ID: 31881093
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract][Full Text] [Related]
5. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis.
Oldroyd A; Sergeant JC; New P; McHugh NJ; Betteridge Z; Lamb JA; Ollier WE; Cooper RG; Chinoy H;
Rheumatology (Oxford); 2019 Apr; 58(4):650-655. PubMed ID: 30535395
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in dermatomyositis-specific autoantibodies.
Fujimoto M; Watanabe R; Ishitsuka Y; Okiyama N
Curr Opin Rheumatol; 2016 Nov; 28(6):636-44. PubMed ID: 27533321
[TBL] [Abstract][Full Text] [Related]
7. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
Matsuura E; Ishiguro N; Katsumata Y; Urano W; Yamanaka H; Kondo M; Kuwana M; Kaji K; Hamaguchi Y; Fujimoto M; Kawashima M
Eur J Dermatol; 2012; 22(5):668-71. PubMed ID: 22992252
[TBL] [Abstract][Full Text] [Related]
8. [Dermatomyositis and Autoantibodies].
Fujimoto M
Brain Nerve; 2018 Apr; 70(4):427-438. PubMed ID: 29632290
[TBL] [Abstract][Full Text] [Related]
9. Presence of anti-transcriptional intermediary factor-1 gamma antibodies in a dermatomyositis patient with retroperitoneal cancer of unknown primary site.
Hori H; Ozeki Y; Kobashigawa T; Futsuhara K; Tanaka A; Watanabe E; Yabe H; Yago T; Fukuchi T; Sugawara H; Kotake S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):62-68. PubMed ID: 33269651
[TBL] [Abstract][Full Text] [Related]
10. Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence.
Fiorentino DF; Mecoli CA; Rosen MC; Chung LS; Christopher-Stine L; Rosen A; Casciola-Rosen L
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 35040440
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection.
Fiorentino D; Casciola-Rosen L
Arthritis Rheum; 2012 Feb; 64(2):346-9. PubMed ID: 21987176
[No Abstract] [Full Text] [Related]
12. Dermatomyositis with anti-TIF1-γ antibodies.
De Greef A; Marot L; Yildiz H; Baeck M
BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30297488
[No Abstract] [Full Text] [Related]
13. Amyopathic dermatomyositis with anti-TIF1 gamma antibodies.
Schiffmann ML; Warneke VS; Ehrchen J
J Dtsch Dermatol Ges; 2018 Jan; 16(1):76-78. PubMed ID: 29232033
[No Abstract] [Full Text] [Related]
14. Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen.
De Vooght J; Vulsteke JB; De Haes P; Bossuyt X; Lories R; De Langhe E
Rheumatology (Oxford); 2020 Mar; 59(3):469-477. PubMed ID: 31883334
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis.
Kotobuki Y; Tonomura K; Fujimoto M
Immunol Med; 2021 Mar; 44(1):23-29. PubMed ID: 32649853
[TBL] [Abstract][Full Text] [Related]
16. Anti-transcriptional intermediary factor 1-γ antibody as a biomarker in patients with dermatomyositis.
Shimizu K; Kobayashi T; Kano M; Hamaguchi Y; Takehara K; Matsushita T
J Dermatol; 2020 Jan; 47(1):64-68. PubMed ID: 31638280
[TBL] [Abstract][Full Text] [Related]
17. A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor.
Varedi D; Frigerio A; Scaife C; Hull C
Dermatol Online J; 2019 Mar; 25(3):. PubMed ID: 30982303
[TBL] [Abstract][Full Text] [Related]
18. Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.
Kubeček O; Soukup T; Paulík A; Kopecký J
BMC Cancer; 2016 Aug; 16(1):684. PubMed ID: 27561848
[TBL] [Abstract][Full Text] [Related]
19. A chronic recurrent disease course of dermatomyositis is associated with autoantibodies against transcriptional intermediary factor 1-γ.
Meisterfeld S; Röber N; Conrad K; Beissert S; Aringer M; Günther C
Br J Dermatol; 2017 Aug; 177(2):590-593. PubMed ID: 28314058
[No Abstract] [Full Text] [Related]
20. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study.
Dani L; Holmqvist M; Martínez MA; Trallero-Araguas E; Dastmalchi M; Svensson J; Labrador-Horrillo M; Selva-O'Callaghan A; Lundberg IE
Clin Exp Rheumatol; 2020; 38(1):67-73. PubMed ID: 31365334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
